Tear Sheet

Company Overview

HTG Molecular Diagnostics, Inc.'s mission is to empower precision medicine at the local level. The company’s proprietary HTG EdgeSeq technology automates multiplexed molecular profiling of nucleic acids in a wide variety of solid and liquid samples, even when very limited in amount. The extraction free workflow paired with detection by next-generation sequencing offers many advantages and enables meaningful applications, such as identifying biomarkers important for precision medicine, understanding the clinical relevance of these biomarkers, and, ultimately, identifying treatment options.

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG Expands RUO Profiling Menu with New Platform Compatibility Assays
HTG EdgeSeq DLBCL Cell of Origin Assay and the HTG EdgeSeq Lung Fusions RUO Assay now available for use on Thermo Fisher Scientific Ion Torrent NGS platform TUCSON, Ariz. , July 15, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is
Toggle Summary HTG Expands Data Analytics Capabilities for Customers with the Release of HTG EdgeSeq Reveal Data Analytics Software Version 1.2.0
TUCSON, Ariz. , July 08, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced the release of its HTG EdgeSeq TM Reveal data analytics software, version 1.2.0.
Toggle Summary HTG Presents at the 11th Annual Edition of the Worldwide Innovative Networking (WIN) Symposium
TUCSON, Ariz. , July 01, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that it presented its technology in an oral presentation at the annual WIN Symposium meeting for personalized
Toggle Summary HTG Molecular Diagnostics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TUCSON, Ariz. , May 24, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that on May 22, 2019 the Compensation Committee of its Board of Directors granted inducement stock options to
Toggle Summary HTG Molecular Diagnostics Reports First Quarter 2019 Results
Call scheduled for today, May 9, at 4:30pm ET TUCSON, Ariz. , May 09, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today reported its financial results for the first quarter ended March 31, 2019

Stock Chart

SEC Filings

Filing date Description

Additional proxy soliciting materials - definitive

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Official notification to shareholders of matters to be brought to a vote ("Proxy")